客服中心
关注我们
全国服务热线：
18086415513
赛培新增产品文章：人IL-17 ELISA试剂盒
发布时间：2022-09-16 16:52:55
组合型人工肝治疗对慢加急性肝功能衰竭患者血清IL-17的影响研究
朱立娜 黄初军 赵秋燕 尹春萍 唐 源* （曲靖市第一人民医院消化内科，云南 曲靖 655000） 【摘要】目的 探讨组合型人工肝治疗对慢加急性肝功能衰竭（ACLF）患者血清白细胞介素 -17（IL-17）的影响。方法 采用流式细胞仪检 测肝损伤组、ACLF 组血清 IL-17 的浓度含量，进一步检测 ACLF 患者进行血浆置换（PE）、双重血浆吸附（DPMAS）、血浆置换 + 双重 血浆吸附（PE+DPMAS）治疗后的浓度，对比 3 组治疗前、治疗后指标变化。结果 ACLF 患者血清 IL-17 与肝损伤组比较有显著性差异 （P ＜ 0.05）。ACLF 患者进行人工肝不同模式治疗比较 ：PE 组患者治疗前后 IL-17 的水平比较有统计学意义（P ＜ 0.05）。DPMAS 组 患者治疗前后 IL-17 浓度含量比较差异有统计学意义（P ＜ 0.05）。PE+DPMAS 组患者治疗前后 IL-17 含量比较差异有统计学意义 （P ＜ 0.05）。PE 组、DPMAS 组、PE+DPMAS 组患者治疗前 IL-17 浓度差异无统计学意义（P ＞ 0.05）；3 组治疗后比较 ：PE+DPMAS 组 与 PE 组、DPMAS 组间 IL-17 浓度差异有统计学意义（P ＜ 0.05）。PE 组与 DPMAS 组比较 IL-17 浓度差异有统计学意义（P ＜ 0.05）。 结论 ① ACLF 患者 IL-17 浓度高于肝损伤组。② PE 组、DPMAS 组、PE+DPMAS 组患者治疗 ACLF 均可以有效清除 IL-17。其中 PE+DPMAS 治疗模式对 ACLF 患者血清 IL-17 的清除效果明显优于 PE 和 DPMAS 治疗组，DPMAS 组清除 IL-17 的能力优于 PE 组。 【关键词】人工肝 ；肝功能衰竭 ；白细胞介素 -17 中图分类号：R575.3 文献标识码：B 文章编号：1671-8194（2021）15-0031-03
Effect of Different Modes of Artificial Liver Therapy on Serum IL-17 in Patients with Acute-on-chronic Liver Failure
ZHU Li'na, HUANG Chujun, ZHAO Qiuyan, YIN Chunping, TANG Yuan* (Department of Digestive Medicine, Qujing First People's Hospital, Qujing 655000, China) [Abstract] Objective To investigate the effects of different modes of artifificial liver therapy on serum interleukin-17(IL-17) in patients with acute-on-chronic liver failure (ACLF). Methods Flow cytometry was used to detect the serum IL-17 concentration in the liver injury group and ACLF group, and to further detect plasma exchange (PE), dual plasma adsorption (DPMAS), plasma exchange + dual plasma adsorption (PE+DPMAS) treatments in ACLF patients after the concentration, compare the index changes of the three groups before and after treatment. Results There was a signifificant difference between serum IL- 17 and liver injury in patients with ACLF(P＜0.05). The comparison of different modes of artifificial liver therapy in patients with ACLF: the differences of serum IL-17 between the pre-and post-treatment of PE group was statistically signifificant(P＜0.05). The differences of serum IL-17 before and after treatment of DPMAS group was statistically signifificant(P＜0.05). The differences of serum IL-17 before and after treatment of PE+DPMAS group was statistically signifificant(P＜0.05). There were no signifificant differences of serum IL-17 between PE group, DPMAS group and PE+DPMAS group before treatment (P＞0.05). After the three groups of treatment, the differences of serum IL-17 between the PE + DPMAS group and the PE group and the DPMAS group was signifificant and statistically signifificant(P＜0.05). The differences of serum IL-17 between PE group and DPMAS group was statistically signifificant(P＜0.05). Conclusion The concentration of cytokine IL-17 in ACLF patients is higher than that in liver injury group. The treatment of acute-on-chronic liver failure in PE group, DPMAS group and PE+DPMAS group could effectively remove the cytokine IL-17. The removal effect of PE+DPMAS treatment model on serum IL-17 in ACLF patients is signifificantly better than that of PE and DPMAS treatment group. The ability of the DPMAS group to clear IL-17 is better than that of the PE group. [Key words] Artifificial liver; Liver failure; Interleukin-17
组合型人工肝治疗对慢加急性...者血清IL-17的影响研究_朱立娜.pdf
